BD IMag[™]

Technical Data Sheet

Anti-Human CD19 Particles - DM

Product Information

Catalog Number:	558497
Size:	5.0 ml
Clone:	4G7
Storage Buffer:	Aqueous buffered solution containing BSA* and 0.09% Sodium Azide

Specificity

BD IMagTM anti-human CD19 Particles - DM are magnetic nanoparticles that have monoclonal antibody conjugated to their surfaces. These particles are optimized for the positive selection or depletion of CD19-bearing leukocytes using the BD IMagnetTM. CD19 is expressed during all stages of B-cell differentiation and maturation, except on plasma cells. CD19 is also present on follicular dendritic cells. It is not found on T cells, NK cells, granulocytes or monocytes.^{1,2,3}



Positive selection and depletion of human CD19-positive cells from PBMC. Leukocytes were labeled with BD IMagTM anti-humanCD19 particles- DM as described in the protocol. After labeling, the cells were separated using the BD IMagnetTM, and the negative (CD19-) and positive (CD19+) fractions were collected. Please refer to the Separation Flow Chart to identify the separated cell populations represented in this figure. For flow cytometric analysis, fresh PBMC (panel A), the negative fraction (Panel B), and the positive fraction (panel C) were stained with APC-conjugated anti-humanCD19 mAb HIB19 (Cat. No. 555916). The percent CD19+ cells in each sample is given.

Storage

The antibody-conjugated magnetic particles should be stored undiluted at 4°C.

Usage

Peripheral Blood Mononuclear Cells (PBMC) are labeled with BD IMagTM anti-human CD19 Particles – DM according to the following Protocol. This labeled cell suspension is then placed within the magnetic field of the BD IMagnetTM (Cat. no. 552311). Labeled cells migrate toward the magnet (positive fraction), leaving the unlabeled cells in suspension so they can be drawn off (negative fraction). The tube is then removed from the magnetic field for resuspension of the positive fraction. The separation is repeated twice to increase the purity of the positive fraction. The magnetic separation steps are diagrammed in the Separation Flow Chart. After the positive fraction is washed, the small size of the magnetic particles allows the positive fraction to be further evaluated in downstream applications such as flow cytometry.

* Source of all serum proteins is from USDA inspected abattoirs located in the United States. BD IMagTM particles are prepared from carboxy-functionalized magnetic particles which are manufactured by Skold Technology.

Hazardous Ingredient: Sodium Azide. Avoid exposure to skin and eyes, ingestion, and contact with heat, acids, and metals. Wash exposed skin with soap and water. Flush eyes with water. Dilute with running water before discharge into plumbing.

BD	Biosciences	Pharmingen

	www.bdbiosciences.com						
	United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean	
	877.232.8995	888.259.0187	32.53.720.211	0120.8555.90	65.6861.0633	55.11.5185.9995	
For country-specific contact information, visit www.bdbiosciences.com/how_to_order /							
Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.							
	PD RD Logo and all other trademarks are the preparty of Porton Dickinson and Company @2003 RD						
Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product toter than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited. For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale. BD. BD. Loog and all other trademarks are the property of Becton. Dickinson and Company. @2003 BD							

b) BD Logo and all other trademarks are the property of Becton, Dickinson at 558497 Rev. 002 05/17/06



SEPARATION FLOW CHART

(The circled numbers correspond to the steps of the following Protocol.)



MAGNETIC LABELING PROTOCOL

- 1. Prepare PBMC from anti-coagulated human blood, preferably by density gradient centrifugation using Ficoll-Paque.TM Remove clumps of cells and/or debris by passing the suspension through a 70-µm nylon cell strainer.
- Dilute BD IMag[™] Buffer (10X) (Cat. no. 552362) 1:10 with sterile distilled water or prepare 1X BD IMag[™] buffer by supplementing 2. Phosphate Buffered Saline with 0.5% BSA, 2 mM EDTA, and 0.09% sodium azide). Store at 4°C.
- 3. Wash cells with an excess volume of 1X BD IMagTM buffer, and carefully aspirate all the supernatant.
- Vortex the BD IMagTM anti-human CD19 Particles DM thoroughly, and add 50 µl of particles for every 10⁷ total cells. 4.
- 5. MIX THOROUGHLY. Incubate at room temperature for 30 minutes.
- Bring the BD IMagTM-particle labeling volume up to 1 8 x 10⁷ cells/ml with 1X BD IMagTM buffer, and immediately place the tube on the BD 6. IMagnetTM. Incubate for 8 - 10 minutes.
- 7. With the tube on the BD IMagnetTM, carefully aspirate off the supernatant. This supernatant contains the negative fraction.
- Remove the tube from the BD IMagnetTM, and add 1 ml of 1X BD IMagTM buffer. Gently resuspend cells by pipetting up and down, and return 8. the tube to the BD IMagnetTM for another 2 - 4 minutes.
- With the tube on the BD IMagnetTM, carefully aspirate off the supernatant and discard. 9.
- 10. Repeat Steps 8 and 9.
- 11. After the final wash step, resuspend the positive fraction in an appropriate buffer or media, and proceed with desired downstream application(s).

A more detailed protocol for the magnetic cell separation appears on the Technical Data Sheet accompanying the BD IMagnetTM (Cat. no. 552311).

The concentration of BD IMagTM anti-human CD19 Particles - DM suggested in the protocol has been optimized for the purification of CD19positive B lymphocytes from human peripheral blood. When labeling target cell populations present at lower frequencies, fewer BD IMagTM particles can be used. Conversely, when labeling target cell populations that are present at higher frequencies, more particles should be used. To determine the optimal concentration of the BD IMagTM anti-human CD19 Particles - DM for a particular application, a titration in two-fold increments is recommended.

NOTE

Avoid nonspecific labeling by working quickly and keeping incubation times to a minimum.

Ficoll-Paque is a trademark of Amersham Biosciences Limited.

References

- 1. Nadler, L.M., K.C. Anderson, G. Matti, et. al. 1983. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen activated, and malignant B lymphocytes. J. Immunol. 131: 244.
- Knapp, W., B. Dorken, E.P. Rieber, et. al., eds. 1989. Leucocyte Typing IV: White Cell Differentiation Antigens, Oxford University Press, New York.
- Schlossman, S., L. Boumsell, W. Gilks, et. al., eds. 1995. Leucocyte Typing V: White Cell Differentiation Antigens, Oxford University Press, New York. 3.

Page 2 of 2

BD Biosciences

BD Biosciences Pharmingen							
www.bdbiosciences.com							
United States 877.232.8995	Canada 888.259.0187	Europe 32.53.720.211	Japan 0120.8555.90	Asia Pacific 65.6861.0633	Latin America/Caribbean 55.11.5185.9995		
For country-spe	ecific contact in	formation, visit v	www.bdbioscien	ces.com/how_to	_order/		
Conditions: The ir of any patents. BL use of our produc product or as a co written authoriza	nformation disclose D Biosciences will n ts. Purchase does r Imponent of anoth tion of Becton Dick	d herein is not to b ot be held responsi not include or carry er product. Any us kinson and Compan	e construed as a rec ble for patent infrin any right to resell o e of this product oth y is strictly prohibite	ommendation to use gement or other vio r transfer this produc ter than the permitt ed.	e the above product in violation lations that may occur with the ct either as a stand-alone ed use without the express		

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale. BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2003 BD 558497 Rev. 002 05/17/06